Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Mette Zander, Sten Madsbad, Jan Lysgaard Madsen et al. · The Lancet · 2002 · 1.3K citations

Medicine, Endocrinology, Internal Medicine +16

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Timothy J. Kieffer, Christopher H.S. McIntosh, Raymond A. Pederson · Endocrinology · 1995 · 1.1K citations

Life Sciences, Biochemistry, Endocrinology +17

(2<i>R</i>)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-<i>a</i>]pyrazin- 7(8<i>H</i>)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:  A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Dooseop Kim, Liping Wang, Maria Beconi et al. · Journal of Medicinal Chemistry · 2004 · 817 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Is There a Difference between Leads and Drugs? A Historical Perspective

Tudor I. Oprea, A. M. Davis, Simon J. Teague et al. · Journal of Chemical Information and Computer Sciences · 2001 · 775 citations

Pharmacy, Medicinal Chemistry, Pharmacology +12

Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects

Carolyn F. Deacon, Michael A. Nauck, M. Toft-Nielsen et al. · Diabetes · 1995 · 716 citations

Medicine, Endocrinology, Pharmacokinetics +7